DOP2016000173A - Heteroarilos y usos de estos - Google Patents

Heteroarilos y usos de estos

Info

Publication number
DOP2016000173A
DOP2016000173A DO2016000173A DO2016000173A DOP2016000173A DO P2016000173 A DOP2016000173 A DO P2016000173A DO 2016000173 A DO2016000173 A DO 2016000173A DO 2016000173 A DO2016000173 A DO 2016000173A DO P2016000173 A DOP2016000173 A DO P2016000173A
Authority
DO
Dominican Republic
Prior art keywords
heteroarilos
myn
vps34
inflammatory
useful
Prior art date
Application number
DO2016000173A
Other languages
English (en)
Inventor
Paul E Fleming
Yongbo Hu
Tianlin Xu
Stephen G Stroud
Jeffrey P Ciavarri
Indu T Bharathan
Chris Blackburn
Jouhara Chouitar
Courtney A Cullis
Natalie D Amore
Kenneth M Gigstad
Krista E Gipson
Mario Girad
Janice Lee
Gang Li
Mansoureh Razaei
Michael D Sintchak
Francois Soucy
Tricia J Vos
He Xu
Yingchun Ye
Tzu-Tshin Wong
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53543363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000173(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of DOP2016000173A publication Critical patent/DOP2016000173A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE LA FÓRMULA I: I Y SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTE, DONDE X, R1, R2, R3, R4, R5, L1, L2, M Y N SON COMO SE DESCRIBIÓ EN LA MEMORIA DESCRIPTIVA.DICHOS COMPUESTOS SON INHIBIDORES DE VPS34 Y, POR LO TANTO, SON ÚTILES PARA TRATAR TRASTORNOS PROLIFERATIVOS, INFLAMATORIOS O CARDIOVASCULARES.
DO2016000173A 2014-01-14 2016-07-12 Heteroarilos y usos de estos DOP2016000173A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461927055P 2014-01-14 2014-01-14
US201462054742P 2014-09-24 2014-09-24

Publications (1)

Publication Number Publication Date
DOP2016000173A true DOP2016000173A (es) 2016-12-15

Family

ID=53543363

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000173A DOP2016000173A (es) 2014-01-14 2016-07-12 Heteroarilos y usos de estos

Country Status (26)

Country Link
US (3) US9802960B2 (es)
EP (1) EP3094325B1 (es)
JP (1) JP6609258B2 (es)
KR (1) KR20160122736A (es)
CN (1) CN105916503B (es)
AP (1) AP2016009368A0 (es)
AU (1) AU2015206652A1 (es)
BR (1) BR112016016289B1 (es)
CA (1) CA2935867C (es)
CL (1) CL2016001805A1 (es)
CR (1) CR20160363A (es)
DO (1) DOP2016000173A (es)
EA (1) EA032458B1 (es)
EC (1) ECSP16067303A (es)
ES (1) ES2908042T3 (es)
GE (1) GEP20196983B (es)
IL (1) IL246755A0 (es)
MX (1) MX2016009135A (es)
MY (1) MY182908A (es)
PE (1) PE20161313A1 (es)
PH (1) PH12016501388A1 (es)
SG (1) SG11201604820XA (es)
TN (1) TN2016000270A1 (es)
TW (1) TWI662024B (es)
UY (1) UY35951A (es)
WO (1) WO2015108861A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230922B (zh) * 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TWI747846B (zh) 2015-10-21 2021-12-01 日商大塚製藥股份有限公司 苯內醯胺化合物
CN108884067B (zh) 2016-02-19 2021-01-08 思普瑞特生物科学公司 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物
RS60898B1 (sr) 2016-02-19 2020-11-30 Sprint Bioscience Ab Jedinjenja 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisna za lečenje kancera i dijabetesa
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
GB201706327D0 (en) * 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
PL3672941T3 (pl) * 2017-08-23 2022-06-13 Sprint Bioscience Ab Związki pirydylopirydonu
CN111094271B (zh) * 2017-08-23 2023-02-28 思普瑞特生物科学公司 吡啶胺-吡啶酮化合物和嘧啶胺-吡啶酮化合物
AU2018321135B2 (en) 2017-08-23 2023-11-23 Sprint Bioscience Ab Azaindolylpyridone and diazaindolylpyridone compounds
CA3073142A1 (en) 2017-08-23 2019-02-28 Sprint Bioscience Ab Morpholinylpyridone compounds
US11076596B2 (en) 2017-09-18 2021-08-03 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020045941A1 (ko) * 2018-08-27 2020-03-05 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CA3153531A1 (en) * 2019-09-11 2021-03-18 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
CN112574207B (zh) * 2019-09-30 2023-04-11 南京药石科技股份有限公司 Erk1/2蛋白激酶抑制剂及其用途
BR112022016124A2 (pt) * 2020-02-13 2022-10-25 Genfleet Therapeutics Shanghai Inc Composto de di-hidronaftiridinona, e método de preparação para este e uso médico deste
EP4251152A1 (en) 2020-11-25 2023-10-04 Deciphera Pharmaceuticals, LLC Pyridylpyridone derivatives as vsp34 inhibitors for use in the treatment of a viral infection
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60330895D1 (de) 2002-11-01 2010-02-25 Vertex Pharma Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
GB0425026D0 (en) * 2004-11-12 2004-12-15 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
US8101770B2 (en) * 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
ZA200704971B (en) * 2004-12-16 2008-09-25 Vertex Pharma Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
CN103641829A (zh) 2006-08-30 2014-03-19 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物
ES2363178T3 (es) 2006-12-04 2011-07-26 Astrazeneca Ab Compuestos de urea policíclicos antibacterianos.
MX2009006536A (es) 2006-12-22 2009-06-26 Novartis Ag Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
EP2173722B1 (en) 2007-07-26 2012-08-29 Novartis AG Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
WO2009039140A1 (en) 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
WO2009155121A2 (en) 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
CN102238950B (zh) 2008-08-04 2014-05-07 Chdi基金会股份有限公司 某些犬尿氨酸-3-单加氧酶抑制剂、药物组合物以及使用方法
WO2010056574A1 (en) 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
WO2010057877A1 (en) * 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
BRPI1010974A2 (pt) 2009-05-22 2019-09-24 Exelixis Inc benzoxazepinas baseada em inibidores p13k/ m tor contra doenças proliferativas
WO2011008915A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
JP2011033670A (ja) * 2009-07-30 2011-02-17 Sony Corp 光学ファインダユニットおよび撮像装置
WO2011026911A1 (en) * 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
SG182803A1 (en) * 2010-02-05 2012-09-27 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
MX2012014537A (es) 2010-07-05 2013-02-21 Merck Patent Gmbh Derivados de bipiridilo utiles para el tratamiento de enfermedades inducidas por cinasa.
WO2012009227A1 (en) 2010-07-16 2012-01-19 N30 Pharmaceuticals, Llc Novel dihydropyridin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists
JP2013532688A (ja) 2010-07-26 2013-08-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
NZ607087A (en) 2010-08-11 2015-05-29 Millennium Pharm Inc Heteroaryls as inhibitors of pi3k and for the treatment of proliferative, inflammatory, or cardiovascular disorders
US8478700B2 (en) 2010-08-11 2013-07-02 Brightedge Technologies, Inc. Opportunity identification and forecasting for search engine optimization
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
WO2012066070A1 (en) 2010-11-17 2012-05-24 Novartis Ag 3-(aminoaryl)-pyridine compounds
CA2822565A1 (en) 2010-12-21 2012-06-28 Novartis Ag Bi-heteroaryl compounds as vps34 inhibitors
ES2531465T3 (es) 2010-12-23 2015-03-16 Sanofi Derivados de pirimidinona, su preparación y su utilización farmacéutica
US8669370B2 (en) * 2011-01-26 2014-03-11 Sanofi Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
JP2014506878A (ja) 2011-01-28 2014-03-20 ノバルティス アーゲー Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
DE102011077104A1 (de) 2011-06-07 2012-12-13 Siemens Aktiengesellschaft Verfahren zur Gewinnung von metallhaltigen Wertstoffen aus einem metallhaltige Wertstoffe enthaltenden suspensionsartigen Massestrom
KR101502500B1 (ko) 2011-07-01 2015-03-16 주식회사 엘지화학 비수 전해액 및 이를 이용한 리튬 이차전지
UA111382C2 (uk) * 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
JP2015506347A (ja) 2011-12-23 2015-03-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
US9458147B2 (en) 2012-02-22 2016-10-04 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
CA2873861C (en) * 2012-04-05 2021-01-19 Boehringer Ingelheim International Gmbh Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
WO2014053533A1 (en) * 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
EP2903613B1 (en) * 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
WO2014083327A1 (en) 2012-11-27 2014-06-05 Md Pharma Ab Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
EP2944637B1 (en) * 2013-01-11 2020-02-19 FUJIFILM Corporation Nitrogen-containing heterocylic compound or salt thereof
US9650358B2 (en) 2013-03-13 2017-05-16 Abbvie Inc. Pyridine CDK9 kinase inhibitors
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TN2016000270A1 (en) * 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US10167279B2 (en) * 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors

Also Published As

Publication number Publication date
US9751854B2 (en) 2017-09-05
GEP20196983B (en) 2019-06-25
EP3094325B1 (en) 2021-10-13
AP2016009368A0 (en) 2016-08-31
US20170073326A1 (en) 2017-03-16
MY182908A (en) 2021-02-05
US9802960B2 (en) 2017-10-31
MX2016009135A (es) 2016-10-05
CL2016001805A1 (es) 2017-07-07
PE20161313A1 (es) 2016-12-17
ES2908042T3 (es) 2022-04-27
EP3094325A4 (en) 2017-08-09
IL246755A0 (en) 2016-08-31
JP6609258B2 (ja) 2019-11-20
US10538533B2 (en) 2020-01-21
KR20160122736A (ko) 2016-10-24
TN2016000270A1 (en) 2017-10-06
TW201613865A (en) 2016-04-16
TWI662024B (zh) 2019-06-11
EA201691421A1 (ru) 2017-05-31
AU2015206652A1 (en) 2016-08-04
BR112016016289B1 (pt) 2023-02-07
EA032458B1 (ru) 2019-05-31
JP2017503813A (ja) 2017-02-02
CA2935867C (en) 2023-04-04
CR20160363A (es) 2016-10-12
US20180118762A1 (en) 2018-05-03
PH12016501388A1 (en) 2016-08-15
ECSP16067303A (es) 2017-02-24
SG11201604820XA (en) 2016-07-28
UY35951A (es) 2015-07-31
EP3094325A1 (en) 2016-11-23
BR112016016289A2 (pt) 2018-05-08
CA2935867A1 (en) 2015-07-23
US20150225422A1 (en) 2015-08-13
CN105916503A (zh) 2016-08-31
CN105916503B (zh) 2020-04-14
WO2015108861A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
DOP2016000173A (es) Heteroarilos y usos de estos
ECSP16088985A (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
UY37018A (es) Inhibidores bicíclicos de pad4
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
TR201900844T4 (tr) Tgf-r sinyal inhibitörleri olarak antisens oligonükleotidler.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
DOP2017000136A (es) Compuestos para tratar el cáncer
BR112018015410A2 (pt) compostos, composições e métodos
ITUB20156862A1 (it) Composizioni per il trattamento della psoriasi.